RT Journal Article
SR Electronic
T1 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP S67
OP S72
DO 10.1097/IGC.0000000000000205
VO 24
IS Supp 3
A1 Amant, Frédéric
A1 Floquet, Anne
A1 Friedlander, Michael
A1 Kristensen, Gunnar
A1 Mahner, Sven
A1 Nam, Eun Ji
A1 Powell, Matthew A.
A1 Ray-Coquard, Isabelle
A1 Siddiqui, Nadeem
A1 Sykes, Peter
A1 Westermann, Anneke M.
A1 Seddon, Beatrice
YR 2014
UL http://ijgc.bmj.com/content/24/Supp_3/S67.abstract
AB Abstract Endometrial stromal sarcoma (ESS) accounts for approximately 20% of all uterine sarcomas and presents, at a mean age, around 50 years of age. Half of the patients are premenopausal. ESS often manifests as an endometrial polyp and 60% of cases present with FIGO stage I disease. The natural history is one of slow growing indolent disease. Typical microscopic findings include a uniform population of endometrial stromal-type cells invading the myometrium and myometrial vessels. Imaging studies cannot reliably diagnose ESS preoperatively, so surgical resection for a presumed fibroid is a common scenario. Hysterectomy is the cornerstone of treatment for localized ESS, but morcellation should be avoided. Systematic lymphadenectomy in ESS does not improve the outcome. Leaving the ovaries in situ does not worsen survival and this is of importance especially for young women. The data support the current practice to administer adjuvant hormonal treatment, although several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors) and duration of therapy. Repeat surgery for recurrent disease that is indolent and hormone sensitive appears to be an acceptable approach. Systemic treatment for recurrent disease is mainly hormonal.